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Abstract
Aims TheMichigan Neuropathy Screening Instrument (MNSI) is used to assess distal symmetrical peripheral neuropathy in
diabetes. It includes two separate assessments: a 15-item self-administered questionnaire and a lower extremity examination
that includes inspection and assessment of vibratory sensation and ankle reflexes. The purpose of this study was to evaluate
the performance of the MNSI in detecting distal symmetrical peripheral neuropathy in patients with Type 1 diabetes and to
develop new scoring algorithms.
Methods The MNSI was performed by trained personnel at each of the 28 Diabetes Control and Complications
Trial ⁄Epidemiology of Diabetes Interventions and Complications clinical sites. Neurologic examinations and nerve con-
duction studies were performed during the same year. Confirmed clinical neuropathy was defined by symptoms and signs of
distal symmetrical peripheral neuropathy based on the examination of a neurologist and abnormal nerve conduction findings
in ‡ 2 anatomically distinct nerves among the sural, peroneal and median nerves.
Results We studied 1184 subjects with Type 1 diabetes. Mean age was 47 years and duration of diabetes was 26 years.
Thirty per cent of participants had confirmed clinical neuropathy, 18% had ‡ 4 and 5% had ‡ 7 abnormal responses on the
MNSI questionnaire, and 33% had abnormal scores (‡ 2.5) on the MNSI examination. New scoring algorithms were
developed and cut points defined to improve the performance of the MNSI questionnaire, examination and the combination
of the two.
Conclusions Altering the cut point to define an abnormal test from ‡ 7 abnormal to ‡ 4 abnormal items improves the
performance of the MNSI questionnaire. The MNSI is a simple, non-invasive and valid measure of distal symmetrical
peripheral neuropathy in Type 1 diabetes.
Diabet. Med. 29, 937–944 (2012)
Keywords measurement, peripheral neuropathy
Abbreviations AUC, area under the receiver operating characteristic curve; DCCT, Diabetes Control and Complica-
tions Trial; EDIC, Epidemiology of Diabetes Interventions and Complications; MNSI, Michigan Neuropathy Screening
Instrument
Introduction
The Michigan Neuropathy Screening Instrument (MNSI) is
used widely for the evaluation of distal symmetrical peripheral
neuropathy in diabetes. The MNSI includes two separate
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assessments, a 15-item self-administered questionnaire that is
scored by summing abnormal responses, and a lower extremity
examination that includes inspection and assessment of vibra-
tory sensation and ankle reflexes and is scored by assigning
points for abnormal findings [1]. The purpose of this study was
to evaluate the sensitivity, specificity, positive and negative
predictive values of the MNSI in detecting distal symmetrical
peripheral neuropathy in patients with Type 1 diabetes and to
develop new scoring algorithms to improve the performance of
the MNSI questionnaire, the examination and the combination
of the two.
Patients and methods
Study sample
At baseline, 1441 men and women between 13 and 39 years of
age with Type 1 diabetes for 1–15 years were enrolled in the
Diabetes Control and Complications Trial (DCCT). Subjects
were randomly assigned to intensive or conventional therapy
and were followed for a mean of 6.5 years [2]. In 1994, 1375
of the surviving DCCT subjects were enrolled in the Epidemi-
ology of Diabetes Interventions and Complications (EDIC)
study (687 intensive therapy, 688 conventional therapy) and
have been followed to the present time.
Scoring the Michigan Neuropathy Screening Instrument
The MNSI questionnaire is self-administered. Responses are
added to obtain a total score. ‘Yes’ responses to questions 1–3,
5–6, 8–9, 11–12, 14–15 are each counted as one point. ‘No’
responses to questions 7 and 13 each count as one point.
Question 4 was considered to be a measure of impaired
circulation and question 10 a measure of general asthenia and
were not included in the published scoring algorithm [1]. A
score of ‡ 7 was considered abnormal [1]. All 15 questions
were included in the new scoring algorithms.
During theMNSI examination, a health professional inspects
each foot for deformities, dry skin, calluses, infections and
fissures. Each foot with any abnormality receives a score of
1. Each foot is also inspected for ulcers and each foot with an
ulcer receives a score of 1. The ankle reflexes are also elicited. If
the reflex is absent, the patient is asked to perform the Jendrassic
manoeuver and, if present, the reflex is designated as present
with reinforcement and is scored as 0.5. If the reflex is absent
with the Jendrassic manoeuver, the reflex is designated as absent
and is scored as 1. Vibration sensation is then tested in the great
toe using a 128-Hz tuning fork. In general, the examiner should
be able to feel vibration in his or her hand for 5 s longer than a
normal subject can at the great toe. Vibration is scored as
present if the examiner senses the vibration on his or her finger
for < 10 s longer than the subject feels it in the great toe,
decreased if sensed for ‡ 10 s (scored as 0.5) or absent (scored as
1). The total possible score is 8 points and, in the published
scoring algorithm, a score ‡ 2.5 is considered abnormal [1].
Definition of distal symmetrical peripheral neuropathy
Board-certified neurologists and electromyographers were
identified, trained and certified by DCCT ⁄EDIC to conduct
neurological evaluations and electrodiagnostic studies [3–5].
Confirmed clinical neuropathy was defined as the presence of
symptoms and signs consistent with distal symmetrical
peripheral neuropathy based on the examination of a board-
certified neurologist and nerve conduction abnormalities in one
or more attribute(s) in a least two anatomically distinct nerves
among the sural, peroneal or median nerves [5].
Statistical analysis
The performance of the MNSI questionnaire and examination
in predicting confirmed clinical neuropathy was assessed by
determining sensitivity, specificity, positive and negative pre-
dictive values in the full cohort. Sensitivity is the probability of
having a positive questionnaire or examination in the presence
of confirmed clinical neuropathy. Specificity is the probability
of having normal (not positive) MNSI tests in the absence of
confirmed clinical neuropathy. Positive predictive value is the
proportion of subjects with neuropathy among those with
positive MNSI questionnaires or examinations. Negative pre-
dictive value is the proportion of subjects without neuropathy
among those with normal (not positive) MNSI tests.
All items on the questionnaire were coded as 0 for a negative
response and 1 for a positive response (negative responses on
items 7 and 13 counted as 1 point). For the examination,
responses for the left and right feet were combined. For each
measure of the examination (appearance, ulcer, reflex and
vibration), a combined score ‡ 1.0 was classified as abnormal.
The sensitivity and specificity of each item in predicting con-
firmed clinical neuropathy was evaluated. Chi-square values
were used to determine the maximum discriminatory capability
of each question.
Beta-coefficients from multiple logistic regression models [6]
were used to develop indices for predicting confirmed clinical
neuropathy based on the 15-item questionnaire alone, the
4-item examination alone and a combination of the two.
Stepwise logistic regression was used to develop a parsimonious
model and Madalla’s R2 based on the model likelihood ratio
was used as a measure of explained variation [7].
Receiver operating characteristic (ROC) curves were used to
illustrate the relationship between the true positive ratio (sen-
sitivity) and the false positive ratio (1-specificity) of a test [8].
Optimal cut points to define abnormal tests were determined
using Bayes decision rule [9], which classifies each subject into
whichever population has the greatest posterior probability.
This is equivalent to selecting a cut-off that maximizes the
proportion correctly classified (PCC) and is computed as the
{(prevalence · sensitivity) + [(1-prevalence) · specificity]},
where the prevalence was estimated from that observed in
EDIC. Areas under the receiver operating characteristic curve
(AUC) are a measure of the performance of a test in predicting
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the outcome of interest. An AUC value of 0.5 indicates that a
test performs no better than chance. AUC values between 0.70
and 0.79 indicate fair test performance, values between 0.80
and 0.89 indicate good performance and values ‡ 0.9 indicate
excellent performance.
Results
During EDIC years 13–14, 1184 subjects with Type 1 diabetes
(89% of eligible subjects) underwent MNSI assessment, a neu-
rologist’s examination and nerve conduction studies. Mean age
( sd) was 47  7 years. Fifty-three per cent of subjects were
men. Average duration of diabetes was 26  5 years. Mean
height was 172  9 cm, mean BMI was 28.2  5.0 kg ⁄m2 and
mean HbA1c was 62  13 mmol ⁄mol (7.8  1.2%). Mean
MNSI questionnaire score was 1.83  2.25 and mean MNSI
examination score was 1.84  1.60. Fifty-six subjects (5%) had
positive MNSI questionnaire scores (‡ 7) and 393 (33%)
subjects had positive examination scores (‡ 2.5) with the
published scoring system [1]. Thirty per cent of subjects had
confirmed clinical neuropathy.
Figures 1a and 1b show the receiver operating characteristic
curves for the performance of the MNSI questionnaire and the
MNSI examination in predicting confirmed clinical neuro-
pathy. The AUC for the MNSI questionnaire and examination
were similar, 0.73 and 0.76, respectively. When the threshold
to define an abnormal test for the MNSI questionnaire was ‡ 7,
the questionnaire was 13% sensitive and 99% specific in
identifying confirmed clinical neuropathy. Positive and negative
predictive values were 84 and 73%, respectively. When the
threshold to define an abnormal test was set at ‡ 4, the ques-
tionnaire was 40% sensitive and 92% specific and had a
positive predictive value of 69% and a negative predictive value
of 78%. When the threshold to define an abnormal MNSI
examination was set at ‡ 2.5, the MNSI examination was 61%
sensitive and 79% specific in defining confirmed clinical neu-
ropathy and had a positive predictive value of 55% and a
negative predictive value of 83%.
Table 1 provides the sensitivity and specificity of each item in
predicting confirmed clinical neuropathy. Sensitivities for the
questionnaire items ranged from 4 to 49%, and specificities
from 74 to 100%. The two questions with the best sensitivity
were question 9 (Ever had diabetic neuropathy?) and ques-
tion 4 (Get muscle cramps in your legs ⁄ feet?). The two ques-
tions with the best specificity, were question 15 (Have you ever
had an amputation?) and question 6 (Hurt when bedcovers
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FIGURE 1 The performance of the Michigan Neuropathy Screening Instrument (MNSI) components for prediction of confirmed clinical neuropathy: (a)
the MNSI questionnaire using the clinical scoring algorithm; (b) the MNSI examination using the clinical scoring algorithm; (c) the MNSI questionnaire
index; (d) the MNSI examination index; (e) the MNSI combined questionnaire and examination index; (f) the MNSI questionnaire index; (g) the MNSI
examination index; (h) the MNSI combined questionnaire and examination index. Graphs (c) to (h) identify the optimal cut-offs from Table 2 such that the
proportion correctly classified is maximized. Additionally, cut-offs with approximately 80% sensitivity and 80% specificity are labelled.
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touch your skin?). The sensitivities for the examination items
ranged from 2 to 72% and the specificities from 66 to 100%
(Table 1). The reduction or absence of an ankle reflex was the
most sensitive item and the presence of an ulcer the most spe-
cific. Items 1 and 9 from the questionnaire and the reduction or
absence of an ankle reflex from the examination also had the
highest v2-values, indicating maximum discriminatory capa-
bility.
Table 2 presents the b-coefficients for each of the items, as
well as the mean, median, standard deviation and range of
calculated MNSI index scores based on the questionnaire
alone, examination alone and a combination of both. The
logistic regression model for the MNSI questionnaire index
explains R2 = 21% of the variance in confirmed clinical
neuropathy. Figure 1c is the receiver operating characteristic
curve showing the performance of the MNSI questionnaire
index in predicting confirmed clinical neuropathy. The AUC is
0.75. The cut-off with the highest probability of correctly
classifying (proportion correctly classified 0.79) confirmed
clinical neuropathy is > 2.0318, with a sensitivity of 38%,
specificity of 96%, positive predictive value of 82% and neg-
ative predictive value of 78%.
Table 1 Performance of the individual components of the Michigan Neuropathy Screening Instrument (MNSI) questionnaire and examination in
predicting confirmed clinical neuropathy
Confirmed clinical
neuropathy Sensitivity Specificity
v2-test*
P-value
Questionnaire No Yes
1. Are your legs and ⁄ or feet numb? No 790 231 34.6% 95.5% 192.1
Yes 37 122 < 0.01
2. Do you ever have any burning pain in your legs
and ⁄ or feet?
No 765 267 25.0% 92.7% 70.9
Yes 60 89 < 0.01
3. Are your feet too sensitive to touch? No 812 326 8.4% 98.2% 29.7
Yes 15 30 < 0.01
4. Do you get muscle cramps in your legs and ⁄ or feet? No 613 203 42.8% 74.1% 33.3
Yes 214 152 < 0.01
5. Do you ever have any prickling feelings in your legs
or feet?
No 724 221 37.6% 87.6% 97.8
Yes 103 133 < 0.01
6. Does it hurt when the bedcovers touch your skin? No 812 332 6.7% 98.3% 20.4
Yes 14 24 < 0.01
7. When you get into the bath or shower, are you able
to tell the hot water from the cold water?
No 46 52 14.6% 94.4% 26.8
Yes 781 304 < 0.01
8. Have you ever had an open sore on your foot? No 712 258 27.3% 86.2% 30.9
Yes 114 97 < 0.01
9. Has your doctor ever told you that you have
diabetic neuropathy?
No 724 180 49.2% 87.9% 190.1
Yes 100 174 < 0.01
10. Do you feel weak all over most of the time? No 809 324 9.0% 97.7% 27.1
Yes 19 32 < 0.01
11. Are your symptoms worse at night? No 750 276 22.0% 91.1% 38.4
Yes 73 78 < 0.01
12. Do your legs hurt when you walk? No 782 299 15.8% 94.6% 33.9
Yes 45 56 < 0.01
13. Are you able to sense your feet when you walk? No 75 39 11.0% 90.9% 1.0
Yes 752 317 0.31
14. Is the skin on your feet so dry that it cracks open? No 732 292 18.0% 88.6% 9.4
Yes 94 64 < 0.01
15. Have you ever had an amputation? No 822 340 4.2% 99.5% 22.0
Yes 4 15 < 0.01
Examination
1. Is the appearance of at least one foot abnormal? No 585 186 47.3% 71.3% 38.1
Yes 235 167 < 0.01
2. Is ulceration present in at least one foot? No 817 348 2.0% 99.5% 5.9
Yes 4 7 0.02
3. Are the ankle reflexes reduced in both feet or absent
in at least one foot?
No 539 99 71.8% 65.9% 140.7
Yes 279 252 < 0.01
4. Is vibration perception reduced in both feet or
absent in at least one foot?
No 616 149 58.2% 75.0% 120.1
Yes 205 207 < 0.01
*Testing that the proportion ‘yes’ on the MNSI questionnaire or examination is the same for those with and without confirmed clinical
neuropathy.
Questions 7 and 13 were reversed scored so that ‘no’ responses indicated an abnormality and counted as one point in the scoring
algorithms. The sensitivities and specificities are based on the reversed 2 · 2 tables.
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The logistic regression model for the MNSI examination
index explains R2 = 17% of the variance in confirmed clinical
neuropathy. Figure 1d is the receiver operating characteristic
curve showing the performance of the MNSI examination
index in predicting confirmed clinical neuropathy. The AUC is
0.76. The cut-off with the highest probability of correctly
Table 2 Performance of the Michigan Neuropathy Screening Instrument (MNSI) index equations in predicting confirmed clinical neuropathy (b-coeffi-
cients  standard errors)
MNSI index*
MSNI
questionnaire
index
MSNI
examination
index
MNSI
combined
index
Reduced
questionnaire
index
Reduced
examination
index
Reduced
combined
index
Questionnaire Beta-coefficients  standard errors 
1. Are your legs and ⁄ or feet numb? 1.55 (0.25) 1.25 (0.27) 1.55 (0.23) 1.21 (0.25)
2. Do you ever have any burning pain
in your legs and ⁄ or feet?
0.26 (0.25) 0.65 (0.27) 0.56 (0.26)
3. Are your feet too sensitive to touch? 0.69 (0.43) 0.56 (0.46)
4. Do you get muscle cramps in your
legs and ⁄ or feet?
0.15 (0.18) 0.03 (0.19)
5. Do you ever have any prickling
feelings in your legs or feet?
0.54 (0.20) 0.51 (0.22) 0.60 (0.18) 0.49 (0.21)
6. Does it hurt when the bedcovers
touch your skin?
)0.63 (0.49) )0.71 (0.52)
7. When you get into the bath or
shower, are you able to tell the hot
water from the cold water?§
0.61 (0.29) 0.65 (0.31)
8. Have you ever had an open sore on
your foot?
0.39 (0.19) 0.20 (0.21) 0.46 (0.18)
9. Has your doctor ever told you that
you have diabetic neuropathy?
1.21 (0.18) 0.83 (0.20) 1.28 (0.17) 0.89 (0.19)
10. Do you feel weak all over most of
the time?
0.27 (0.40) 0.32 (0.44)
11. Are your symptoms worse at night? )0.53 (0.26) )0.45 (0.27)
12. Do your legs hurt when you walk? 0.18 (0.29) 0.15 (0.31)
13. Are you able to sense your feet
when you walk?§
)0.22 (0.27) )0.21 (0.29)
14. Is the skin on your feet so dry that
it cracks open?
0.10 (0.22) )0.01 (0.23)
15. Have you ever had an amputation? 0.92 (0.77) 0.65 (0.85)
Examination
1. Is the appearance of at least one
foot abnormal?
0.63 (0.15) 0.44 (0.17) 0.65 (0.15) 0.46 (0.16)
2. Is ulceration present in at least one
foot?
1.28 (0.77) 0.80 (0.92)
3. Are the ankle reflexes reduced or
absent in at least one foot?
1.33 (0.15) 1.21 (0.17) 1.33 (0.15) 1.22 (0.16)
4. Is vibration perception reduced or
absent in at least one foot?
1.01 (0.15) 0.60 (0.17) 1.01 (0.15) 0.60 (0.16)
Model R2 21% 17% 27% 20% 17% 26%
Descriptive statistics for indices
n 1157 1158 1132 1172 1160 1149
Mean (sd) 0.77 (1.16) 1.18 (1.03) 2.30 (1.46) 0.70 (1.09) 1.17 (1.02) 1.45 (1.39)
Median 0.16 1.33 2.01 0.00 1.17 1.22
Range ()0.85, 5.58) (0.00, 4.24) ()0.13, 8.38) (0.00, 3.88) (0.00, 2.99) (0.00, 5.43)
Area under the receiver operating char-
acteristic curve
0.75 0.76 0.81 0.74 0.76 0.81
Optimal cut-off 2.0318 1.9524 3.2883 1.2760 1.9798 2.7703
*Each index was computed as the sum of the b-coefficients for all items for which there was a positive response possibly indicating distal
symmetrical peripheral neuropathy.
Data are b-coefficients  standard errors from multiple logistic regression models. Coefficients were used to derive MNSI indices for
predicting confirmed clinical neuropathy.
The cut-off such that the proportion correctly classified is maximized.
§Questions 7 and 13 were reversed scored so that ‘no’ responses indicated an abnormality and counted as one point in the scoring
algorithms.
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classifying (proportion correctly classified 0.74) confirmed
clinical neuropathy is > 1.9524, with a sensitivity of 45%,
specificity of 87%, positive predictive value of 60% and neg-
ative predictive value of 79%.
The logistic regression model for the combined questionnaire
and examination index explains R2 = 27% of the variance in
confirmedclinical neuropathy. Figure 1e is the receiveroperating
characteristic curve showing the performance of the MNSI
combined index. The AUC is 0.81. The cut-off with the highest
probability of correctly classifying (proportion correctly classi-
fied 0.80) confirmed clinical neuropathy is > 3.2883, with a
sensitivityof48%, specificityof93%,positivepredictivevalueof
74% and negative predictive value of 81%.
Table 2 also presents the reduced models based on stepwise
regression. Only four questions entered the reduced index
derived from the questionnaire, three items entered the reduced
index derived from the examination and seven items entered
the reduced index derived from the questionnaire and exami-
nation. Figures 1f, 1g, and 1h show the performance of the
reduced MNSI questionnaire index, examination index and
combined questionnaire and examination index in predicting
confirmed clinical neuropathy. The logistic regression models
explained R2 = 20, 17 and 26% of the variance, respectively.
AUCs were 0.74, 0.76 and 0.81, respectively. The optimal cut-
offs for achieving the highest probability of correctly classifying
confirmed clinical neuropathy are > 1.2760 for the reduced
MNSI questionnaire (proportion correctly classified 0.78,
sensitivity 46%, specificity 92%, positive predictive value 72%
and negative predictive value 80%), > 1.9798 for the reduced
MNSI examination (proportion correctly classified 0.74, sen-
sitivity 45%, specificity 87%, positive predictive value 60%
and negative predictive value 79%) and > 2.7703 for the
combined MNSI index (proportion correctly classified 0.80,
sensitivity 43%, specificity 95%, positive predictive value 80%
and negative predictive value 80%). These reduced models
perform nearly as well as the more extensive models.
Discussion
Distal symmetrical peripheral neuropathy is a frequent com-
plication of diabetes [10]. Historically, the diagnosis of distal
symmetrical peripheral neuropathy has been based upon
symptoms, signs and electrophysiological testing. More recent
consensus guidelines have also recommended quantitative
sensory testing and consideration of intraepidermal nerve fibre
density as diagnostic tests [11–13]. Unfortunately, clinical
examinations require specially trained and experienced
personnel, nerve conduction studies and quantitative sensory
testing require special equipment and skin biopsies are invasive.
Therefore, simple non-invasive clinical tests that assess symp-
toms and signs have been developed and used, especially in
clinical trials [14,15]. The MNSI is one such test. The MNSI
was first proposed in 1994 [1]. Since then, it has been widely
used to assess distal symmetrical peripheral neuropathy in
clinical practice and in large clinical trials, including the
DCCT ⁄EDIC, the Action to Control Cardiovascular Disease in
Diabetes (ACCORD) (16) and the Bypass Angioplasty Revas-
cularization Investigation 2 Diabetes (BARI 2D) [17].
During years 13–14 of EDIC, the DCCT ⁄EDIC cohort with
Type 1 diabetes had the MNSI performed and underwent
neurologic examinations and electrodiagnostic testing [5]. This
provided an opportunity to reassess the performance of the
MNSI in detecting distal symmetrical peripheral neuropathy
and to develop new scoring algorithms. When used separately,
the MNSI questionnaire (AUC 0.73) and examination
(AUC 0.76) performed similarly in predicting confirmed clinical
neuropathy.We found, however, that the published cut point to
define a positive test for the questionnaire (‡ 7) was very
insensitive, missing many patients with confirmed clinical neu-
ropathy. Changing the cut point to define a positive test for the
questionnaire to ‡ 4 harmonized the sensitivity and specificity
of the MNSI questionnaire and the MNSI examination.
We then examined the performance of each item in the
MNSI questionnaire and examination in predicting confirmed
clinical neuropathy. The two questions with the highest sensi-
tivity were question 9 (ever had diabetic neuropathy?) and
question 4 (get muscle cramps in your legs ⁄ feet?). The two
questions with the highest specificity were question 15 (have
you ever had an amputation?) and question 6 (hurt when
bedcovers touch your skin?). The reduction or absence of an
ankle reflex was the most sensitive examination item and the
presence of an ulcer the most specific. Our finding that ques-
tion 4 (get muscle cramps in your legs ⁄ feet?) was the second
most sensitive for confirmed clinical neuropathy was of interest
because it had previously been excluded from the published
scoring algorithm as it was deemed to be a measure of impaired
circulation and not neuropathy. We suspect that question 4
was a sensitive question because it is a common symptom
associated with increased activity in poorly conditioned sub-
jects, medications including diuretics and statins, vascular
insufficiency and muscle denervation and re-innervation. The
fact that question 4 was the least specific question for distal
symmetrical peripheral neuropathy supports this hypothesis.
We next used multivariate logistic regression to derive an
MNSI questionnaire index, an MNSI examination index and a
combined index to predict confirmed clinical neuropathy. The
AUCs were 0.75, 0.76 and 0.81, respectively. Finally, using
stepwise logistic regression, we developed parsimonious models
from the questionnaire, examination and combined question-
naire and examination. Only seven items entered the reduced
index derived from both the questionnaire and examination
and the reduced model performed nearly as well as the more
extensive models.
The strength of our study was its large size, the uniform
assessment of distal symmetrical peripheral neuropathy at all
28 EDIC sites and the rigorous methods used to test the sen-
sitivity and specificity of the MNSI. The major limitation is that
our study involved relatively young patients with Type 1
diabetes of long duration and with a moderate prevalence
(30%) of distal symmetrical peripheral neuropathy. The
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performance of the MNSI may be different in older populations
with Type 2 diabetes and additional co-morbidities. In addition,
the positive predictive value of theMNSI will not be as robust in
populations with lower prevalences of distal symmetrical
peripheral neuropathy. Finally, DCCT ⁄EDIC patients had been
followed for many years and were usually aware of their
neuropathy status. While this might have biased their responses
to question 9 (Has your doctor ever told you that you have
diabetic neuropathy?), analyses performed including and
excluding responses to question 9 did not substantially impact
our results (see also Supporting Information, Appendix S1).
Our analyses confirm that the MNSI is a simple, non-inva-
sive and valid measure of distal symmetrical peripheral neu-
ropathy when compared with gold standard diagnostic testing
that includes neurological examinations performed by board-
certified neurologists and standardized electrophysiology
examinations. The MNSI can be used in clinical practice and in
large clinical trials to assess distal symmetrical peripheral neu-
ropathy. Altering the cut point to define an abnormal ques-
tionnaire from ‡ 7 abnormal to ‡ 4 abnormal items improves
the performance of the MNSI questionnaire relative to the
examination, and defining a combined MNSI index further
increases the sensitivity and specificity of the instrument.
Assigning scores based on weights derived from multivariate
regression models further improves the performance of the
questionnaire, examination and the combination of the two.
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predicting confirmed clinical neuropathy eliminating question 9.
Please note: Wiley-Blackwell are not responsible for the content
or functionality of any supporting materials supplied by the
authors. Any queries (other than for missing material) should
be directed to the corresponding author for the article.
DIABETICMedicine Michigan Neuropathy Screening Instrument in Type 1 diabetes • W. H. Herman et al.
944 Published 2012. This article is a US Government work and is in the public domain in the USA
